Cancer Immunity & Immunotherapy
Wednesday, June 20 at FOCIS 2018
The purpose of this course is to review tumor immunology as the scientific foundation for the current practice of cancer immunotherapy, emphasizing fundamental principles, recent clinical advances, current limitations, and near-term opportunities for further accelerating clinical progress.
This course is designed for translational researchers and scientists, practicing clinicians, trainees, and indviduals in biotechnology and pharmaceutical companies interested in immuno-oncology and the development of immunotherapies for cancer.
Completion of this course, will allow participants to:
The 2018 course agenda will be announced in fall 2017. In the meantime, please reference the 2017 course agenda below.
|2017 Course Agenda|
|Wednesday, June 14|
|8:00am - 9:00am||The Mechanistic Basis of Cancer Immunotherapy - Leisha Emens, MD, PhD|
|9:00am - 9:40am||Manipulating the Tumor Environment (DCs, Tregs, others) - Vincenzo Bronte, PhD|
|9:40am - 10:00am||Break
|10:00am-10:40am||CAR-T Cell Therapy: Principles and Current Practices - Carl June, MD|
|10:40am - 11:20am||CAR-T Cell Therapy: Next Generation CARs Toxicities, Challenges and Prospects - Carl June, MD
|11:20am-12:00pm||TCR-based Adoptive Cell Therapy - Cassian Yee, MD
|12:00pm - 12:45pm||Lunch with Faculty|
|12:45pm - 1:30pm||Checkpoint Blockade Therapy: Current Status & Biomarkers - Hassane Zarour, MD
|1:30pm - 2:10pm||Next Generation Checkpoint and Combination Therapies - Hassane Zarour, MD
|2:10pm - 2:50pm||Focus on Engineered Antibodies (BiTE/other) - Dario Neri, PhD|
|2:50pm - 3:30pm||Immune-Related Toxicity: Mechanisms and Management - Kevan Herold, MD|
|3:30pm - 3:45pm||Break|
|3:45pm - 4:30pm||Vaccination Strategies, Identification of Neoantigens - Catherine Wu, MD|
|4:30pm - 5:00pm||Future Prospects and Challenges in Cancer Immunotherapy - Jeffrey Bluestone, PhD|